The Food and Drug Administration (FDA) has granted accelerated approval to Voyxact ® (sibeprenlimab-szsi) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for ...

The FDA’s Priority Review designation allows for a shortened review period (within 6 months) from the time of application acceptance.

GLP-1 RA use with subsequent prepregnancy or early pregnancy discontinuation linked to higher risk for preterm delivery, gestational diabetes ...

Association strongest for those with cannabis use disorder compared with cannabis users without abuse or dependence or nonusers.

March of Dimes report shows high rates of preterm birth, infant mortality, as well as worsening sociodemographic disparities.

Extensive safety testing and manufacturing improvements have now made it possible to bring the drug back to the US market.